Our results suggest that therapeutic strategies to restore the Th1/Th2 immune balance should be explored in CTCL, and existing UPR-inducing drugs, like Btz, or novel HSPA5/6-selective inhibitors are potential candidates for pursuing that objective. This evidence concerns the gene CASC3 and primary cutaneous T-cell non-Hodgkin lymphoma.